Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MT1988
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Forster Foundation
Deal Size : $1.2 million
Deal Type : Financing
Monument Therapeutics Secures £1M for Schizophrenia Program Growth
Details : The funding will support the clinical development of MT1988, a novel fixed-dose combination drug for the treatment of cognitive impairment associated with schizophrenia.
Brand Name : MT1988
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 15, 2024
Lead Product(s) : MT1988
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Forster Foundation
Deal Size : $1.2 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?